tumor mutational burden
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
Association for Molecular Pathology Releases New Tumor Mutational Burden Testing Recommendations
The joint consensus guideline, authored by AMP, ASCO, CAP, and SITC, seeks to establish evidence-based standards for validation and reporting of TMB tests in the clinic.
Neoantigen Detection Platform Picks up T-Cell Responses to Tumor Mutations
Researchers combined tumor sequence, transcriptome, and patient immune cell response clues in their tumor-specific neoantigen detection and validation platform.
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.
Large Study of Early-Onset Colorectal Cancer Patients IDs Unique, Potentially Actionable Mutations
In younger patients, HER2 mutations were more prevalent in those who had MSI-high/TMB-high tumors, while POLE mutations were more common in MSS/TMB-high tumors, researchers reported at ASCO.